Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL804146 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL16967371 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL5862033 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL804233 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL4674647 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL7415779 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| Hydrochloric Acid SCHEMBL5860905 | 0.98 | DPP4 (0.52) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL7710838 | 0.85 | DPP4 (0.52) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL4676515 | 0.85 | ALOX5 (0.53) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL25178201 | 0.83 | ESR1 (0.46) | LMNAHIF1AKDM4ECYP2D6SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021081110-A2 | PEPTIDES AND USE THEREOF | ANEXIGEN, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-9540620-B2 | Methods and compositions for modulating G-alpha-Q signaling | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150218538-A1 | Methods and Compositions for Modulating G-Alpha-Q Signaling | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| US-20090198084-A1 | PROCESS FOR THE DEPROTECTION OF PROTECTED AMINES | DSM IP ASSETS B.V. (NL) | 2009-08-06 | — | — | US | disclosed |
| US-20090198084-A1 | PROCESS FOR THE DEPROTECTION OF PROTECTED AMINES | DSM IP ASSETS B.V. (NL) | 2009-08-06 | — | — | US | disclosed |
| US-20090198084-A1 | PROCESS FOR THE DEPROTECTION OF PROTECTED AMINES | DSM IP ASSETS B.V. (NL) | 2009-08-06 | — | — | US | disclosed |
| EP-2013161-A1 | PROCESS FOR THE DEPROTECTION OF PROTECTED AMINES | DSMIP Assets B.V. (NL) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007128463-A1 | PROCESS FOR THE DEPROTECTION OF PROTECTED AMINES | DSM IP ASSETS B.V. (NL) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007128463-A1 | PROCESS FOR THE DEPROTECTION OF PROTECTED AMINES | DSM IP ASSETS B.V. (NL) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198084-A1 | PROCESS FOR THE DEPROTECTION OF PROTECTED AMINES | BCAT2, ADH1C, BCAT1 | DPP4 3588/4885LMNA 1025/4885ADRA2A 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.